Clarivate Unveils 2026 Drugs to Watch Report Highlighting 11 Transformative Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: PRnewswire
- Blockbuster Drug Identification: Clarivate's 2026 Drugs to Watch report identifies 11 therapies expected to achieve over $1 billion in annual sales within five years, showcasing its foresight and influence in drug development.
- Market Potential Analysis: The report highlights that obesity drug sales are projected to reach $150 billion by 2035, emphasizing the strategic importance of meeting market demands and enhancing clinical value of drugs.
- Innovation Trends: The report underscores advancements in precision oncology and immunology, particularly innovations in protein degraders and oral immunology agents, which will enhance patient access and improve treatment outcomes, driving ongoing industry growth.
- Global Market Dynamics: With Mainland China emerging as a critical commercial market, domestic developers are advancing competitive therapies that shape global strategies in oncology, metabolic disease, and immunology, reflecting the complexity and opportunities in the global market.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like CLVT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on CLVT
Wall Street analysts forecast CLVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLVT is 3.90 USD with a low forecast of 3.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
0 Buy
3 Hold
2 Sell
Moderate Sell
Current: 2.740
Low
3.00
Averages
3.90
High
5.00
Current: 2.740
Low
3.00
Averages
3.90
High
5.00
About CLVT
Clarivate Plc is a global provider of transformative intelligence. The Company offers enriched data, insights and analytics, workflow solutions and expert services in the areas of Academia & Government (A&G), Intellectual Property (IP) and Life Sciences & Healthcare (LS&H). Within the A&G segment, the Company offers solutions across various areas, which include scientific and academic research, information solutions and library software. Its ProQuest One solutions provide access to multidisciplinary curated content across a variety of formats, including data bases, dissertations, news, primary sources, books, and video. Within the IP segment, the Company provides IP data, software, and expertise to other companies to manage and protect critical IP assets. This segment's service offerings include IP management software, Patent services and Brand IP solutions, among others. Within the LS&H segment, the Company offers solutions across research and development, commercial and Medtech.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Clarivate to Announce Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Clarivate Plc will report its Q4 and full year 2025 financial results before market open on February 24, 2026, providing critical financial data for investor analysis.
- Investor Conference Call: The company will host a conference call and webcast at 9:00 AM ET on the same day to review the financial results, potentially including forward-looking information to enhance transparency.
- Webcast Access: Investors can access the live webcast through the investor relations section of the company's website, ensuring all stakeholders can participate and receive the latest updates, fostering engagement with investors.
- Replay Availability: A replay of the earnings call will be available two hours after the live event and will remain accessible for one year, ensuring that investors who cannot attend in real-time can still obtain relevant information, enhancing information accessibility.
Continue Reading
Alight Inc and Other Industrials Stocks Oversold with RSI Near 30
- Alight Inc Rating Adjustment: Keybanc analyst maintains an Overweight rating on Alight but lowers the price target from $6 to $2.5, resulting in a 20% stock decline over the past month, with an RSI of 29.4 indicating potential undervaluation.
- Clarivate PLC Downgrade Impact: Goldman Sachs analyst downgrades Clarivate from Buy to Neutral and cuts the price target from $4.2 to $3.6, leading to a 19% stock drop in the past month, with an RSI of 29 suggesting a possible short-term rebound opportunity.
- CBIZ Inc New Rating: Deutsche Bank initiates coverage on CBIZ with a Hold rating and a price target of $60, despite a 16% stock decline over the past five days, with an RSI of 27.6 indicating signs of being undervalued.
- Market Signal Analysis: Benzinga Pro signals indicate a potential breakout for CBIZ shares, even as its stock dipped 2.6% to $44.97 on Wednesday, reflecting market interest and potential investment opportunities.
Continue Reading